Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TX200-TR101 in living-donor kidney transplant recipients
NL-OMON56213Phase 2Recruiting
- Sponsor
- Sangamo Therapeutics
- Start
- Sep 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TX200 in kidney allograft rejection and organ allograft rejection, sponsored by Sangamo Therapeutics. Primary endpoint: Incidence and grade of TEAEs including SAEs within 28 days. Started Sep 2021; status: recruiting.
02
Drugs
TX200
03
Conditions
kidney allograft rejectionorgan allograft rejection
Beyond the preview
Go deeper on NL-OMON56213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56213.